3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS)

Ann N Y Acad Sci. 1998 May 13:841:811-6. doi: 10.1111/j.1749-6632.1998.tb11022.x.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 4-Aminopyridine / analogs & derivatives*
  • 4-Aminopyridine / pharmacokinetics
  • 4-Aminopyridine / therapeutic use
  • 4-Aminopyridine / toxicity
  • Administration, Oral
  • Amifampridine
  • Animals
  • Follow-Up Studies
  • Humans
  • Lambert-Eaton Myasthenic Syndrome / drug therapy*
  • Mice
  • Myasthenia Gravis / drug therapy
  • Potassium Channels / physiology
  • Time Factors

Substances

  • Potassium Channels
  • 4-Aminopyridine
  • Amifampridine